Faculty profile

Jan-Willem Henning

ResearcherMedicineUniversity of Calgary

This profile is built from public research funding records (CIHR, NSERC and SSHRC) and PubMed. We have not imported them from a University of Calgary directory, so their courses and email address may be missing. Find their university profile.

Jan-Willem Henning

Researcher

Medicine

Health Sciences

University of Calgary

Calgary, Alberta, Canada

Supervision signals

Has led research grants, which requires an independent research appointment. Ask their department whether they supervise graduate students.
21 publications in the last five years, latest in 2026.
Senior (last) author on 4 recent papers, a sign of leading a research group.
Principal investigator on 1 research grant (1 CIHR), most recently in 2023.

These signals come from public records, including CIHR, NSERC and SSHRC funding decisions. Ask the professor or the graduate program whether they are taking new students.

Academic metrics

Publications

Citations

h-index

Collaborators

Grants

Publications by year

Counts cover the works listed on the university profile; citation counts come from Dimensions.

Profiles and links

Search on Google Scholar

Find them onX · LinkedIn · Bluesky · YouTube

Signals and details

Research

Alveolar Soft Part Sarcoma Car T Immunotherapy Renal Cell Carcinoma Sarcoma Triple-Negative Breast Cancer

Latest papers

Correction to: A Canadian real‑world, multi‑center, prospective, observational study assessing the treatment duration, the treatment sequence, and the overall survival for patients treated with endocrine therapy ± targeted therapy in HR + HER2‑negative advanced breast cancer.
Breast cancer research and treatment · 2026
Practical management of antineoplastic-induced nausea and vomiting from antibody-drug conjugates: Insights from a Canadian expert panel.
Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners · 2026
A Canadian real-world, multi-center, prospective, observational study assessing the treatment duration, the treatment sequence, and the overall survival for patients treated with endocrine therapy ± targeted therapy in HR + HER2-negative advanced breast cancer.
Breast cancer research and treatment · 2025

All 25 publications

Latest funding

A Phase I Feasibility and Safety Study of GCAR1, a Chimeric Antigen Receptor (CAR) T-cell Therapy for Patients with Relapsed/Refractory GPNMB-Expressing Solid Tumors
CIHR · 2023 · Principal investigator
$2,796,075

All 1 grants and awards

25 publications.

Correction to: A Canadian real‑world, multi‑center, prospective, observational study assessing the treatment duration, the treatment sequence, and the overall survival for patients treated with endocrine therapy ± targeted therapy in HR + HER2‑negative advanced breast cancer.

Doyle C, Lohmann AE, Iqbal N, Henning JW, Kulkarni S, Califaretti N, Hilton J, Ferrario C, Bouganim N, Mates M, Guillemette S, Leite R, Caron MA, Thireau F, Machado A, Chia S

Breast cancer research and treatment2026

DOI: 10.1007/s10549-026-07934-4 PMID: 41854885

Practical management of antineoplastic-induced nausea and vomiting from antibody-drug conjugates: Insights from a Canadian expert panel.

Jerzak KJ, Snow S, Henning JW, Bouganim N, Besse L

Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners2026

DOI: 10.1177/10781552261441533 PMID: 41989188

A Canadian real-world, multi-center, prospective, observational study assessing the treatment duration, the treatment sequence, and the overall survival for patients treated with endocrine therapy ± targeted therapy in HR + HER2-negative advanced breast cancer.

Doyle C, Lohmann AE, Iqbal N, Henning JW, Kulkarni S, Califaretti N, Hilton J, Ferrario C, Bouganim N, Mates M, Guillemette S, Leite R, Caron MA, Thireau F, Machado A, Chia S

Breast cancer research and treatment2025

DOI: 10.1007/s10549-024-07580-8 PMID: 39847203

Real World Evidence Study to Assess Incidence, Treatment Patterns, Clinical Outcomes, and Health Care Resource Utilization in Early-Stage, High-Risk HER2-Negative Breast Cancer in Alberta, Canada.

Henning JW, Boyne DJ, Brenner DR, Carbonell C, Shokar S, Granados DP, Parackal A, Cheung WY

Clinical breast cancer2025First author

DOI: 10.1016/j.clbc.2024.10.008 PMID: 39547858

Clinician's guide: expert insights on the use of CDK4/6 inhibitors in patients with early breast cancer.

Hussain M, Brezden-Masley C, Chia S, Curigliano G, Webster M, Henning JW

Therapeutic advances in medical oncology2025Senior author

DOI: 10.1177/17588359251326710 PMID: 40125419

Retrospective database analysis to assess treatment patterns, clinical outcomes, and healthcare resource utilization in metastatic or recurrent HER2-positive breast cancer in Alberta.

Basmadjian RB, Cheung WY, Boyne DJ, Henning JW, Moldaver D, Shokar S, Carbonell C, Brenner DR

Cancer treatment and research communications2025

DOI: 10.1016/j.ctarc.2025.101021 PMID: 41167012

Multidisciplinary Practical Guidance for Implementing Adjuvant CDK4/6 Inhibitors for Patients with HR-Positive, HER2-Negative Early Breast Cancer in Canada.

Jerzak KJ, Sehdev S, Boileau JF, Brezden-Masley C, Califaretti N, Edwards S, Gordon J, Henning JW, LeVasseur N, Railton C

Current oncology (Toronto, Ont.)2025

DOI: 10.3390/curroncol32080444 PMID: 40862813

Pan-Canadian consensus recommendations for GIST management in high- and low-throughput centres across Canada.

Beecroft JR, Brar S, Feng X, Hamilton T, Han-Lee C, Henning JW, Josephy PD, Khalili K, Ko YJ, Lemieux C, Liu DM, MacDonald DB, Noujaim J, Pollett A, Salawu A, Saleh R, Smrke A, Warren BE, Zbuk K, Razak AA

Therapeutic advances in medical oncology2024

DOI: 10.1177/17588359241266179 PMID: 39386314

Acceptability, feasibility and preliminary effects of an online group psychotherapy intervention for adolescents and young adults with cancer.

Tutelman PR, Moran C, Beattie SM, Khu M, Howlett M, Scheidl J, Boychuk A, Silveira K, Henning JW, Schulte FSM

Psycho-oncology2024

DOI: 10.1002/pon.6335 PMID: 38526517

Treatment Patterns and Health Outcomes among Patients with HER2 IHC0/-Low Metastatic or Recurrent Breast Cancer.

Farah E, Carbonell C, Boyne DJ, Brenner DR, Henning JW, Moldaver D, Shokar S, Cheung WY

Cancers2024

DOI: 10.3390/cancers16030518 PMID: 38339269

Write to this professor

A short, specific email works best. This draft uses one of their recent papers; replace the parts in brackets with your own details before sending.

Applying for

Paper to mentionMention their CIHR grant from 2023

Subject: Prospective PhD student: Alveolar Soft Part Sarcoma Dear Professor Henning, My name is [your name], and I am a [your current degree or role] at [your institution]. I am applying for a PhD position starting in [term and year]. I read your paper "Correction to: A Canadian real‑world, multi‑center, prospective, observational study assessing the treatment duration, the treatment sequence, and the overall survival for patients treated with endocrine therapy ± targeted therapy in HR + HER2‑negative advanced breast cancer." (2026), and it connects closely to my own work on [your research topic]. [One or two sentences on what you did and what you learned.] I also saw your CIHR-funded project "A Phase I Feasibility and Safety Study of GCAR1, a Chimeric Antigen Receptor (CAR) T-cell Therapy for Patients with Relapsed/Refractory GPNMB-Expressing Solid Tumors" (2023), and I would be glad to contribute to work in that direction. Are you accepting new PhD students for [term and year]? I have attached my CV and transcripts, and I would be glad to talk at a time that suits you. Thank you for your time. Kind regards, [your name]

Something wrong or missing on this profile? Suggest a correction

Jan-Willem Henning

Research

Latest papers

Latest funding

Correction to: A Canadian real‑world, multi‑center, prospective, observational study assessing the treatment duration, the treatment sequence, and the overall survival for patients treated with endocrine therapy ± targeted therapy in HR + HER2‑negative advanced breast cancer.

Practical management of antineoplastic-induced nausea and vomiting from antibody-drug conjugates: Insights from a Canadian expert panel.

A Canadian real-world, multi-center, prospective, observational study assessing the treatment duration, the treatment sequence, and the overall survival for patients treated with endocrine therapy ± targeted therapy in HR + HER2-negative advanced breast cancer.

Real World Evidence Study to Assess Incidence, Treatment Patterns, Clinical Outcomes, and Health Care Resource Utilization in Early-Stage, High-Risk HER2-Negative Breast Cancer in Alberta, Canada.

Clinician's guide: expert insights on the use of CDK4/6 inhibitors in patients with early breast cancer.

Retrospective database analysis to assess treatment patterns, clinical outcomes, and healthcare resource utilization in metastatic or recurrent HER2-positive breast cancer in Alberta.

Multidisciplinary Practical Guidance for Implementing Adjuvant CDK4/6 Inhibitors for Patients with HR-Positive, HER2-Negative Early Breast Cancer in Canada.

Pan-Canadian consensus recommendations for GIST management in high- and low-throughput centres across Canada.

Acceptability, feasibility and preliminary effects of an online group psychotherapy intervention for adolescents and young adults with cancer.

Treatment Patterns and Health Outcomes among Patients with HER2 IHC0/-Low Metastatic or Recurrent Breast Cancer.

A Phase I Feasibility and Safety Study of GCAR1, a Chimeric Antigen Receptor (CAR) T-cell Therapy for Patients with Relapsed/Refractory GPNMB-Expressing Solid Tumors

Frequent collaborators

John Hilton

Muriel Brackstone

Ipshita Prakash

Ian Stuart Dayes

Shannon Puloski

Aaron Pollett

Fiona Schulte

Colleen Cuthbert

Winson Cheung

Ramy Saleh

Som Mukherjee

Mona Shafey

Elizabeth Kurien

Michael Monument

Jan-Willem Henning

Research

Latest papers

Latest funding

Practical management of antineoplastic-induced nausea and vomiting from antibody-drug conjugates: Insights from a Canadian expert panel.

A Canadian real-world, multi-center, prospective, observational study assessing the treatment duration, the treatment sequence, and the overall survival for patients treated with endocrine therapy&#x2009;&#xb1;&#x2009;targeted therapy in HR&#x2009;+&#x2009;HER2-negative advanced breast cancer.

Real World Evidence Study to Assess Incidence, Treatment Patterns, Clinical Outcomes, and Health Care Resource Utilization in Early-Stage, High-Risk HER2-Negative Breast Cancer in Alberta, Canada.

Clinician's guide: expert insights on the use of CDK4/6 inhibitors in patients with early breast cancer.

Retrospective database analysis to assess treatment patterns, clinical outcomes, and healthcare resource utilization in metastatic or recurrent HER2-positive breast cancer in Alberta.

Multidisciplinary Practical Guidance for Implementing Adjuvant CDK4/6 Inhibitors for Patients with HR-Positive, HER2-Negative Early Breast Cancer in Canada.

Pan-Canadian consensus recommendations for GIST management in high- and low-throughput centres across Canada.

Acceptability, feasibility and preliminary effects of an online group psychotherapy intervention for adolescents and young adults with cancer.

Treatment Patterns and Health Outcomes among Patients with HER2 IHC0/-Low Metastatic or Recurrent Breast Cancer.

A Phase I Feasibility and Safety Study of GCAR1, a Chimeric Antigen Receptor (CAR) T-cell Therapy for Patients with Relapsed/Refractory GPNMB-Expressing Solid Tumors

Frequent collaborators

John Hilton

Muriel Brackstone

Ipshita Prakash

Ian Stuart Dayes

Shannon Puloski

Aaron Pollett

Fiona Schulte

Colleen Cuthbert

Winson Cheung

Ramy Saleh

Som Mukherjee

Mona Shafey

Elizabeth Kurien

Michael Monument

A Canadian real-world, multi-center, prospective, observational study assessing the treatment duration, the treatment sequence, and the overall survival for patients treated with endocrine therapy ± targeted therapy in HR + HER2-negative advanced breast cancer.